AstraZeneca sells beta-blocker commercial rights for $300m
22-05-2017
rawpixel / iStockphoto.com
Pharmaceutical company Recordati suffered a setback last week after the EU General Court dismissed its appeal over a trademark registration.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Recordati, trademark, EU trademark, EU General Court, Laboratorios Normon, biotechnology, trademark registration, Laboratorios Normon
